We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
It was a low-key week for the biotech sector with no major updates. Regulatory and pipeline updates from a few players were in focus.
Recap of the Week’s Most Important Stories:
Vertex, CRSP Gene Therapy Label Expansion: Vertex Pharmaceuticals (VRTX - Free Report) and partner CRISPR Therapeutics (CRSP - Free Report) announced that the FDA has expanded the label of their one-shot gene therapy Casgevy (exagamglogene autotemcel) to treat transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. This approval comes ahead of the target action date in March. The gene therapy won FDA approval last month for sickle cell disease in the same age group. Consequently, Casgevy became the first gene therapy utilizing the Nobel prize-winning CRISPR technology. This technology can selectively delete, modify or correct a disease-causing abnormality in a specific DNA segment.
Vertex and CRISPR collaborated in 2015 to focus on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. Casgevy is the first treatment to emerge from the joint research program. Under an amended agreement, Vertex now leads the global development, manufacturing and commercialization of exa-cel and splits program costs and profits worldwide in the ratio of 60:40 with CRISPR.
Allakos Plunges on Updates: Allakos (ALLK - Free Report) plummeted after it announced that its two mid-stage studies evaluating its lead pipeline drug lirentelimab (AK002) in two inflammatory conditions were unsuccessful. Results from top-line data of the two studies — the phase II ATLAS study and phase IIb MAVERICK study — which evaluated lirentelimab in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) indications, respectively, failed to achieve their primary endpoints. Allakos will not pursue further clinical development of lirentelimab.
Concurrently, Allakos announced a restructuring program to reduce costs. Allakos will reduce its workforce by 50% following the failure of lirentelimab in mid-stage studies. It will now focus on clinical development of AK006 along with additional preclinical programs. The reduction is expected to extend the company’s cash runway into mid-2026.
Solid’s Gene Therapy Gets Orphan Drug Tag: Solid Biosciences Inc. (SLDB - Free Report) announced that the FDA has granted the orphan drug designation to its next-generational investigational candidate, SGT-003, which is being developed as a gene therapy for Duchenne muscular dystrophy (DMD). The orphan drug designation will grant Solid Biosciences market exclusivity for SGT-003 in the treatment of DMD for a predefined period, along with the exemption of FDA application fees and tax credits for qualified clinical studies, all subject to approval. The investigational gene therapy already enjoys the FDA’s fast-track designation in the United States for the treatment of DMD.
The company is currently in the process of securing approvals from the institutional review boards (IRB) at the clinical study sites to begin the planned phase I/II study of SGT-003 for DMD. Patient screening for the early to mid-stage DMD will commence shortly after the IRB approvals are secured.
Following patient screening, Solid Biosciences anticipates beginning dosing in the phase I/II DMD study of SGT-003 in the mid-to-late first quarter of 2024.
The Nasdaq Biotechnology Index has lost 2.12% in the past four trading sessions. Among the biotech giants, Vertex has gained 2.36% during the period. Over the past six months, shares of Amgen have surged 35.6%. (See the last biotech stock roundup here: Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results)
Image Source: Zacks Investment Research
What's Next in Biotech?
Stay tuned for more pipeline updates.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
It was a low-key week for the biotech sector with no major updates. Regulatory and pipeline updates from a few players were in focus.
Recap of the Week’s Most Important Stories:
Vertex, CRSP Gene Therapy Label Expansion: Vertex Pharmaceuticals (VRTX - Free Report) and partner CRISPR Therapeutics (CRSP - Free Report) announced that the FDA has expanded the label of their one-shot gene therapy Casgevy (exagamglogene autotemcel) to treat transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. This approval comes ahead of the target action date in March. The gene therapy won FDA approval last month for sickle cell disease in the same age group. Consequently, Casgevy became the first gene therapy utilizing the Nobel prize-winning CRISPR technology. This technology can selectively delete, modify or correct a disease-causing abnormality in a specific DNA segment.
Vertex and CRISPR collaborated in 2015 to focus on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. Casgevy is the first treatment to emerge from the joint research program. Under an amended agreement, Vertex now leads the global development, manufacturing and commercialization of exa-cel and splits program costs and profits worldwide in the ratio of 60:40 with CRISPR.
Allakos Plunges on Updates: Allakos (ALLK - Free Report) plummeted after it announced that its two mid-stage studies evaluating its lead pipeline drug lirentelimab (AK002) in two inflammatory conditions were unsuccessful. Results from top-line data of the two studies — the phase II ATLAS study and phase IIb MAVERICK study — which evaluated lirentelimab in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) indications, respectively, failed to achieve their primary endpoints. Allakos will not pursue further clinical development of lirentelimab.
Concurrently, Allakos announced a restructuring program to reduce costs. Allakos will reduce its workforce by 50% following the failure of lirentelimab in mid-stage studies. It will now focus on clinical development of AK006 along with additional preclinical programs. The reduction is expected to extend the company’s cash runway into mid-2026.
Solid’s Gene Therapy Gets Orphan Drug Tag: Solid Biosciences Inc. (SLDB - Free Report) announced that the FDA has granted the orphan drug designation to its next-generational investigational candidate, SGT-003, which is being developed as a gene therapy for Duchenne muscular dystrophy (DMD). The orphan drug designation will grant Solid Biosciences market exclusivity for SGT-003 in the treatment of DMD for a predefined period, along with the exemption of FDA application fees and tax credits for qualified clinical studies, all subject to approval. The investigational gene therapy already enjoys the FDA’s fast-track designation in the United States for the treatment of DMD.
The company is currently in the process of securing approvals from the institutional review boards (IRB) at the clinical study sites to begin the planned phase I/II study of SGT-003 for DMD. Patient screening for the early to mid-stage DMD will commence shortly after the IRB approvals are secured.
Following patient screening, Solid Biosciences anticipates beginning dosing in the phase I/II DMD study of SGT-003 in the mid-to-late first quarter of 2024.
Solid Biosciences currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance
The Nasdaq Biotechnology Index has lost 2.12% in the past four trading sessions. Among the biotech giants, Vertex has gained 2.36% during the period. Over the past six months, shares of Amgen have surged 35.6%. (See the last biotech stock roundup here: Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results)
Image Source: Zacks Investment Research
What's Next in Biotech?
Stay tuned for more pipeline updates.